



Ricky K. Hsu,^{1,2} Michael Senson,³ Jennifer S. Fusco,⁴ Laurence Brunet,⁴ Brooke Levis,⁴ Quateka Cochran,⁵ Gayathri Sridhar,⁶ Vani Vannappagari,⁶ Kimberley Brown,⁶ Jean Van Wyk,⁷ Michael B. Wohlfeiler,⁸ Gregory P. Fusco⁴



¹NYU Langone Medical Center, New York, NY; ²AIDS Healthcare Foundation, New York, NY; ³CAN Community Health, Fort Lauderdale, FL; ⁴Epividian, Raleigh, NC; ⁵AIDS Healthcare Foundation, Fort Lauderdale, FL; ⁶Viiv Healthcare, Durham, NC; ⁷Viiv Healthcare, London, UK; ⁸AIDS Healthcare Foundation, Miami, FL

Background

- CAB+RPV LA is the first and only complete LA ART regimen approved for HIV-1 treatment in the US
 - Approved by the FDA as Q1M (2021) or Q2M (2022) pairs of injections
 - Indicated for treatment-experienced individuals who are virologically suppressed (VL < 50 copies/mL)
- Real-world studies have reported off-label use among individuals viremic (VL ≥ 50 c/mL) at CAB+RPV LA initiation

Objective

Describe demographics, clinical characteristics, and virologic outcomes among individuals on CAB+RPV LA, stratified by viral load at initiation

Methods

OPERA Cohort

- Prospectively captured, routine clinical data from US-based EHRs, representing ~14% of people with HIV in the US

Inclusion Criteria

- ART-experienced adults, ≥ 18 years of age
- Initiated CAB+RPV LA from 21JAN2021 – 31DEC2024

Censoring Criteria

- Discontinuation of CAB+RPV LA
 - Q1M: > 67 days after last injection
 - Q2M: > 127 days after last injection
- Death
- Lost to follow-up (12 months after last clinical contact)
- End of analysis period (28FEB2025)

Stratification


- Two study groups based on VL at initiation of CAB+RPV LA:
 - VL < 50 c/mL
 - VL ≥ 50 c/mL

Analysis & Outcomes

- Virologic outcomes were assessed among individuals who completed initiation (i.e., received initiation injections ≤ 67 days apart) and had ≥ 1 VL through 28FEB2025
 - Among individuals with VL < 50 copies/mL at initiation**
 - Virologic suppression was maintained if all VLs or the last follow-up VL was < 50 c/mL
 - CVF was defined as 2 consecutive VLs ≥ 200 c/mL or discontinuation of CAB+RPV LA after a VL ≥ 200 c/mL
 - Among individuals with VL ≥ 50 copies/mL at initiation**
 - Virologic suppression was achieved if any or the last follow-up VL was < 50 c/mL
 - CVF was assessed after virologic suppression to < 50 c/mL
- Adherence to maintenance injection dosing was described among complete initiators with ≥ 1 maintenance injection

Results

Figure 1. CAB+RPV LA usage among individuals with VL < 50 c/mL (green) and VL ≥ 50 c/mL (purple) at initiation^a



^a There were an additional 95 individuals who were missing VL at initiation, 79 (83%) of whom completed initiation. Of complete initiators, 69 (87%) received ≥ 1 maintenance injection, and of those individuals, 50 (72%) received all maintenance injections on time.
^b On-time maintenance injections were ≤ 37 days (Q1M) or ≤ 67 days (Q2M) after the previous injection

Table 1. Demographic characteristics at CAB+RPV LA initiation

	VL < 50 c/mL N = 4,587	VL ≥ 50 c/mL N = 582
Age, median years (IQR)	38 (32, 50)	40 (32, 51)
Age ≥ 50 years, n (%)	1,124 (25)	155 (27)
Female sex, n (%)	668 (15)	153 (26)
Black race, n (%)	1,950 (43)	313 (54)
Hispanic ethnicity, n (%)	1,442 (31)	122 (21)
PWID, n (%)	265 (6)	47 (8)
Receiving care in US South, n (%)	2,494 (54)	338 (58)

Table 2. Clinical characteristics at CAB+RPV LA initiation

	VL < 50 c/mL N = 4,587	VL ≥ 50 c/mL N = 582
Years since HIV diagnosis, median (IQR)	6 (2, 12)	8 (2, 16)
Years since ART initiation, median (IQR)	3 (1, 7)	4 (1, 8)
History of AIDS-defined events, n (%)	1,048 (23)	210 (36)
VL (c/mL), median (IQR)	19 (19, 20)	120 (60, 2,040)
VL $\geq 1,000$ c/mL, n (%)	N/A	160 (27)
CD4 cell count (cells/ μ L), median (IQR)	707 (528, 913)	549 (342, 781)
BMI, median (IQR)	27 (24, 31)	27 (23, 31)
BMI ≥ 30 kg/m ² , n (%)	1,380 (30)	169 (29)
Any comorbidity ^a , n (%)	3,600 (79)	473 (81)
Mental health disorders, n (%)	1,767 (39)	276 (47)
Substance misuse, n (%)	897 (20)	161 (28)
Endocrine disorders	2,417 (53)	300 (52)

^a Categories included: Autoimmune disease, cardiovascular disease, invasive cancers, endocrine disorders, mental health disorders, liver disease, bone disorders, peripheral neuropathy, renal disease, hypertension, and substance misuse

Abbreviations: ART, antiretroviral therapy; BMI, body mass index; c/mL, copies per milliliter; CAB+RPV LA, cabotegravir plus rilpivirine long-acting; CVF, confirmed virologic failure; EHR, electronic health record; HIV, immunodeficiency virus; IQR, interquartile range; LA, long-acting; n, number; N/A, not applicable; PWID, people who inject drugs; Q1M, every 1 month; Q2M, every 2 months; US, United States; VL, viral load

Table 3. Adherence among complete initiators with ≥ 1 maintenance injection

	VL < 50 c/mL N = 3,746	VL ≥ 50 c/mL N = 460
Any delayed injection, n (%)	1,581 (42)	202 (44)
Number of delayed injections, median (IQR)	1 (1, 2)	1 (1, 2)
Any delay of 1 to 30 days, n (%)	1,288 (81)	161 (80)
Days after the target window ^a , median (IQR)	3 (2, 9)	4 (2, 10)
Any delay of ≥ 31 days, n (%)	354 (22)	40 (20)
Days after the target window ^a , median (IQR)	52 (45, 56)	52 (45, 55)

^a Target window: ≤ 37 and ≤ 67 days after previous maintenance injection, for Q1M and Q2M dosing respectively

Table 4. Persistence among complete initiators

	VL < 50 c/mL N = 4,196	VL ≥ 50 c/mL N = 529
Months on CAB+RPV LA until first censoring event, median (IQR)	14 (7, 23)	12 (7, 22)
Still on CAB+RPV LA at the end of the analysis period, regardless of discontinuation, n (%)	3,279 (78)	388 (73)
Months on CAB+RPV LA, median (IQR)	16 (9, 26)	15 (8, 26)

Table 5. Virologic effectiveness among complete initiators

	VL < 50 c/mL N = 4,196	VL ≥ 50 c/mL N = 529
≥ 1 VL after initiation, n (%)	4,000 (95)	502 (95)
Last VL < 50 c/mL, n (%)	3,786 (95)	399 (79)
Suppressed at all follow-up VLs, n (%)	3,233 (81)	N/A
Achieved suppression, n (%)	N/A	439 (87)
Experienced CVF, n (%)	43 (1)	7 (2)

Discussion

- Among 5,264 adults initiating CAB+RPV LA, 4,587 (87%) had a VL < 50 c/mL, 582 (11%) had a VL ≥ 50 c/mL, and 95 (2%) were missing VL at initiation (Figure 1)
- Compared to individuals who were suppressed at CAB+RPV LA initiation, individuals who were viremic (Tables 1 & 2):
 - Were more likely to be female and to be Black
 - Were less likely to be Hispanic
 - Had greater time since HIV diagnosis and ART initiation
 - Were more likely to have history of an AIDS-defining event, mental health disorders, and substance misuse
- Among individuals with a VL at initiation who completed initiation and had ≥ 1 maintenance injection, a majority (56%-58%) received all maintenance injections on time (Figure 1)
- Among complete initiators who had ≥ 1 delayed maintenance injection (Table 3):
 - The median number of delayed injections was 1 (IQR: 1, 2)
 - Most individuals experienced delays of < 30 days, with median delays after the target window of 3 days (VL < 50 c/mL) or 4 days (VL ≥ 50 c/mL)
 - The median days after the target window among individuals who experienced delays of ≥ 31 days was 52
- A majority remained on CAB+RPV LA at last follow-up (VL < 50 c/mL: 78%, VL ≥ 50 c/mL: 73%) (Table 4):
 - Median time on CAB+RPV LA was 16 (IQR: 9, 26) and 15 (IQR: 8, 26) months among the VL < 50 c/mL and ≥ 50 c/mL groups, respectively
- In the VL < 50 c/mL group, 81% were suppressed at all follow-up VLs, 95% had a last VL < 50 c/mL, and only 1% experienced CVF (Table 5)
- In the VL ≥ 50 c/mL group, 87% achieved suppression over follow-up, 79% had a last VL < 50 c/mL, and only 2% experienced CVF (Table 5)

Key Findings

- Regardless of VL at initiation of CAB+RPV LA, virologic suppression was commonly achieved/maintained while CVF was rare
- Findings from this large, real-world cohort study reinforce CAB+RPV LA as a versatile and effective therapy for a diverse population, including people struggling with adherence or tolerability to oral regimens

Acknowledgements

This research would not be possible without the generosity of people living with HIV and their OPERA caregivers. Additionally, we are grateful for the following individuals: Lito Torres (SAS programming), Kelly Oh (QA), Bernie Stooks (IT/data management), Lisa Lutz & Nicole Shaw (data architecture), Judy Johnson (medical terminology classification), and Rachel Palmieri Weber (poster creation).

Support

This research was sponsored by Viiv Healthcare



Disclaimer

This content was acquired following an unsolicited medical information enquiry by a healthcare professional. Always consult the product information for your country, before prescribing a ViiV medicine. ViiV does not recommend the use of our medicines outside the terms of their license. In some cases, the scientific Information requested and downloaded may relate to the use of our medicine(s) outside of their license.